SUMMARY Thirty three children aged 2 to 42 months (mean 9 months) with gastro-oesophageal reflux and peptic oesophagitis took part in a treatment trial comparing cimetidine (20 mg/kg/day) with an intensive regimen of antacids (Maalox, 700 mmol (mEq)/1.73 m2/day 
SUMMARY Thirty three children aged 2 to 42 months (mean 9 months) with gastro-oesophageal reflux and peptic oesophagitis took part in a treatment trial comparing cimetidine (20 mg/kg/day) with an intensive regimen of antacids (Maalox, 700 mmol (mEq)/1.73 m2/day). All children were evaluated clinically and by radiology, acid reflux test, and endoscopy. After 12 weeks of treatment all were again evaluated clinically, by pH measurement, and endoscopy. Twenty Thirty three children, 20 boys and 13 girls aged 2 to 42 months of age (mean, 9 months), met the criteria for gastro-oesophageal reflux with oesophagitis. Thirteen had a different final diagnosis including gastro-oesophageal reflux without oesophagitis (five), cows' milk protein intolerance (three), coeliac disease (two), intestinal malrotation (one), and urinary tract infections (two).
Children with a diagnosis of gastro-oesophageal reflux and oesophagitis were allocated in a randomised fashion to 12 weeks' treatment with either cimetidine syrup (20 mg/kg/day) or liquid magnesium hydroxide and aluminum hydroxide in a dose of 700 mmol (mEq)/1 -73 ml/day, one and three hours after meals, and at bedtime. All children underwent positional treatment (infants remained in an infant chair for the whole day and six inch blocks were put under the head of the bed of children older than 1 year) and received fractionated feeds. In infants, formula milk was thickened by adding cereals or Nestargel (1%). At the end of a 12 week period of intensive treatment the children's condition was evaluated by a careful history and physical examination, pH measurement, and an upper endoscopy. Their condition after treatment was classified on the basis of the presence of remaining symptoms, reflux on pH measurement, and endoscopic features of oesophagitis. Children were regarded as 'cured' if the clinical, pH, and endoscopic parameters became normal; 'improved' if findings in at least one of the three parameters had ameliorated; and 'unchanged' or 'worsened' if there was no improvement or deterioration, respectively. Patients who improved underwent a further month of treatment and were again assessed clinically, by pH measurement and by endoscopy. During the trial, children were seen as outpatients every three weeks to assess symptoms and drug compliance. Parents were instructed to report daily, in a diary, symptoms as well as body weight and food intake. At each examination, haemoglobin, haematocrit, red and white blood cell count, alkaline phosphatase, electrolytes, serum calcium, and phosphorus were evaluated in all children. Creatinine, blood urea nitrogen, transaminase, and a-glutamyltransferase were measured additionally in children on cimetidine treatment. A scoring system was used to evaluate children admitted to the trial (Table 1) . The pH measurement, Erythema with friability and exudate.
'Erosions, ulcerations.
In both and t the score was increased by 3 points in presence of hiatal hernia.
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Results
The symptoms and physical findings in 33 children with gastro-oesophageal reflux and oesophagitis are reported in Table 2 ; either vomiting or regurgitation, or both, and a low body weight were the most frequently encountered. Anorexia, hypochromic anaemia, and haematemesis also occurred. Respiratory complications such as recurrent pneumonia or apnoea were present in 18% of the children studied. Twenty nine children completed the trial (15 on antacid and 14 on cimetidine). Two patients in the cimetidine group were excluded because of poor drug compliance, and two children in the antacid group were excluded because of diarrhoea and subsequent reduced antacid intake. The parameters of gastro-oesophageal reflux of both groups are shown in Table 3 ; these were comparable statistically. Twelve children had both a body weight and a weight:height ratio below the fifth centile before treatment. In seven (three on cimetidine and four on antacid) both parameters became normal after 12 weeks' treatment. Five children (three on cimetidine and two on antacid) were gaining weight, but their weight:height ratio still remained below the fifth centile. Three of four patients who had a body weight below the fifth centile but a normal weight: height ratio before treatment showed a body weight within normal limits after 12 weeks of treatment (two on cimetidine and one on antacid); the fourth child (on antacid) still had a weight below the fifth centile.
As shown in Table 4 , there was a significant reduction in the scores of clinical, pH measurement, and endoscopic findings in both groups. At the end of the 12 week trial, eight patients on antacid and seven on cimetidine were cured, five patients on antacid and six on cimetidine improved and two patients on antacid and one on cimetidine remained unchanged. The latter three patients underwent surgery ( Table 5 ). The basal lower oesophageal sphincter pressure before treatment did not correlate with the total score after treatment (including clinical, pH measurement, and endoscopic scores) in either the cimetidine treated (r:0.25; NS) or antacid treated groups (r:0-32; NS). tNo statistically significant difference between the two groups of patients (P> ().1)5). tTen patients were affected by hiatal hernia (6 on antacid and 4 on cimetidine). 25 The results of the present trial indicate that medical treatment of gastro-oesophageal reflux and peptic oesophagitis in children is effective in relieving the symptoms of reflux and in promoting healing of the oesophagitis. Antacids administered in high doses, proved to be as effective as cimetidine in healing peptic oesophagitis. These results differ from those in adults in whom healing of peptic oesophagitis was not consistently achieved by medical treatment. This may be explained by the natural course of gastro-oesophageal reflux disease in children.
The natural history of gastro-oesophageal reflux in infants was well described by Carre in 1959. 26 Sixty per cent of these children become asymptoma-tic at the age of 18 months even without any treatment, five per cent will develop an oesophageal stricture, five per cent will die, and 30% will have persisting symptoms. Therefore, one may reasonably expect a beneficial effect from medical treatment in children. There are good reasons for accepting that in children over the age of 2 years the course of the reflux disease is not much different from that in adults where gastro-oesophageal reflux seems to be a long lasting problem. Infants with sporadic regurgitations may be successfully managed by careful handling, frequent, small feeds, and maintaining an upright position after feeding. Children with moderate symptoms of reflux will benefit from postural manoeuvres and from thickened fractionated feeds. Medical treatment of gastrooesophageal reflux in children is required in the presence of oesophagitis and systemic symptoms such as respiratory complications, failure to thrive, anaemia, and anorexia.
Better understanding of the pathogenesis of gastro-oesophageal reflux9 25 may result in more adequate treatment. As basal lower oesophageal pressure does not seem to be correlated with the occurrence of oesophagitis and with the final outcome of treatment, efforts should also be concentrated on such measures as increasing gastric pH and oesophageal and gastric motility. The newly available antisecretory drugs such as H2 receptor antagonists do not seem to be more effective than antacids in treating reflux in children. The latter, however, in order to be effective, have to be administered in exceedingly high doses, with possible side effects.27 New drugs acting on gastrooesophageal motility such as bethanechol (a cholinergic agent)3 4 and domperidone (a dopamine antagonist)28 are promising treatments for the future.
Further controlled treatment trials comparing different drugs and including a placebo group are necessary to determine the most effective treatment for children with gastro-oesophageal reflux. 
